吉西他滨联合洛铂治疗蒽环类及紫杉类耐药转移性乳腺癌的临床观察

Gemcitabine and lobaphatin combination chemotherapy for metastatic breast cancer patients with anthracycline and taxane resistance

目的:观察吉西他滨联合洛铂方案治疗蒽环类及紫杉类耐药转移性乳腺癌的疗效及不良反应。方法:采用吉西他滨联合洛铂方案治疗蒽环类及紫杉类均耐药转移性乳腺癌32例。吉西他滨1000mg/m2,静脉滴入,d1、d8;洛铂30mg/m2,静脉滴入,d2。化疗以21d为1个周期,至少应用2个周期。结果:32例患者治疗有效率43.7%,中位疾病进展时间为5.8个月,无化疗相关死亡病例。主要不良反应为骨髓抑制及胃肠道反应。结论:吉西他滨联合洛铂方案对蒽环类及紫杉类均耐药的转移性乳腺癌有较好的近期疗效,不良反应可耐受,为有效的解救方案。

OBJECTIVE：To investigate the efficacy and toxicity of gemcitabine combined lobaphatin regimen as chemotherapy for anthracycline and taxane resistant metastatic breast cancer （MBC）. METHODS： Thirty-two patients were treated by gemcitabine combined with lobaphatin regimen. All the patients had failures and relapse after previous treatment with anthracycline and taxane. The regimen was 1 000 mg/m2 gemcitabine, d1, d8, and 30 mg/m2 lobaphatin d2. The treatments were repeated every 21 d and all the patients received at least 2 cycles. RESULTS： The overall response rate was 43.7%. The median time to progression （TTP） was 5.8 months. No patients died in correlated with the gemcitabine combined with lobaphatin regimen.Myelosuppression and gastrointestinal tract reaction were the most common toxicities. CONCLUSIONS： Gemcitabine combined with lobaphatin regimen is well effective for patients with anthracycline and taxane resistant MBC.Drug-related toxicities are tolerable.This regimen can be considered as salvage regimen for those patients.